Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ocular Therapeutix, Inc. - Common Stock
(NQ:
OCUL
)
8.305
-0.165 (-1.95%)
Streaming Delayed Price
Updated: 10:57 AM EDT, Jul 31, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ocular Therapeutix, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings
↗
May 05, 2025
Ocular Therapeutix shares are trading lower by 13.3% Monday afternoon. The company reported worse-than-expected Q1 financial results.
Via
Benzinga
Earnings Scheduled For May 5, 2025
↗
May 05, 2025
Via
Benzinga
Expert Outlook: Ocular Therapeutix Through The Eyes Of 5 Analysts
↗
April 08, 2025
Via
Benzinga
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
↗
April 08, 2025
Via
Benzinga
What 4 Analyst Ratings Have To Say About Ocular Therapeutix
↗
March 18, 2025
Via
Benzinga
Why Ocular Therapeutix Was Bumping Higher This Week
↗
March 14, 2025
Via
The Motley Fool
Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts
↗
December 03, 2024
Via
Benzinga
A Peek at Ocular Therapeutix's Future Earnings
↗
November 13, 2024
Via
Benzinga
Beyond The Numbers: 8 Analysts Discuss Ocular Therapeutix Stock
↗
August 01, 2024
Via
Benzinga
Deep Dive Into Ocular Therapeutix Stock: Analyst Perspectives (6 Ratings)
↗
June 14, 2024
Via
Benzinga
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside
↗
March 11, 2025
Needham starts coverage on Ocular Therapeutix with a Buy rating, citing Axpaxli's potential in wet AMD and forecasting $1.5 billion peak sales.
Via
Benzinga
This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
↗
March 11, 2025
Via
Benzinga
Ocular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A Comeback
↗
March 03, 2025
The company also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet AMD, shifting the timeline from Q4 2025 to Q1 2026.
Via
Stocktwits
Earnings Scheduled For March 3, 2025
↗
March 03, 2025
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
January 13, 2025
Via
Benzinga
3 Biotech Stocks to Sell in August Before They Crash & Burn
↗
August 06, 2024
Investors should keep a watchful eye out for these three biotech stocks to sell before a potential dip damages their gains.
Via
InvestorPlace
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
June 20, 2024
Via
Benzinga
Earnings Scheduled For November 14, 2024
↗
November 14, 2024
Via
Benzinga
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
↗
June 20, 2024
Via
Benzinga
This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
↗
June 20, 2024
Via
Benzinga
Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday
↗
June 20, 2024
Via
Benzinga
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
June 14, 2024
Via
Benzinga
Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday
↗
June 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
May 28, 2024
Via
Benzinga
OCUL Stock Earnings: Ocular Therapeutix Misses EPS, Misses Revenue for Q1 2024
↗
May 07, 2024
OCUL stock results show that Ocular Therapeutix missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
May 06, 2024
Via
Benzinga
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
May 06, 2024
Via
Benzinga
2 Small-Cap Growth Stocks With Room To Run
↗
April 24, 2024
These two small-cap growth stocks could be ready to run.
Via
The Motley Fool
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
April 19, 2024
Via
Benzinga
Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder
↗
April 18, 2024
Ocular Therapeutix's Phase 1 HELIOS study unveils Axpaxli's efficacy in treating non-proliferative diabetic retinopathy. Significant DRSS improvement with no worsening observed. Positive Phase 2 data...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
